Hikma appoints former Fresenius Kabi exec as CSO and head of R&D

15 January 2018

Jordan-headquartered Hikma Pharmaceuticals (LSE: HIK) today announced that Surendera Tyagi will join the company as group chief scientific officer and global head of R&D.

Dr Tyagi will focus on the group’s non-injectables business during the first year and will become a member of the executive committee of Hikma, which is encountering difficulties in gaining regulatory clearance for its generic version of GlaxoSmithKline’s blockbuster asthma drug Advair (fluticasone).

“Surendera is an outstanding scientist with a proven track record of leading research and development in some of the world’s largest and most successful pharmaceutical organizations,” commented Saïd Darwazah, chairman and chief executive of Hikma. “Research and Innovation is one of our five pillars for growth and the appointment of Surendera is a significant step forward in executing on this strategy. We are very excited for Surendera to be joining us and accelerating our ability to develop novel ways to improve the health of people around the world,” he added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK